Session Information

ACLC 2018

IASLC Asia Conference on Lung Cancer 2018

Access Abstracts and Powerpoint Slides to select presentations that took place during the IASLC Asia Conference on Lung Cancer 2018 in Guangzhou, China from November 8 - 10, 2018. This package is available for no charge to active IASLC Members.
Presentation Date(s):
- November 8 - 10, 2018
- Total Presentations: 137
Register to Attend WCLC Switch to Virtual Meeting
Enter Virtual Meeting Access Code

All Days Wednesday
November 7 Wed
Nov 7 Thursday
November 8 Thu
Nov 8 Friday
November 9 Fri
Nov 9 Saturday
November 10 Sat
Nov 10

Filter Results:

Show Only CME Accredited Sessions

28127

+
Best abstracts selected from submissions 6
- 16:20 - 17:00
- 11/09/2018
- Location: Crystal Ballroom 3
- Type: Oral Session
- Track:
- 28231
  
  +
  
  OA11 - First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (?10 mut/Mb): Results From CheckMate 227
  
  22:20 - 22:30 | Presenter: K. Park, J. Lee, H. Sakai, K. Lee, Y. Ohe, S. Kim, T. Fukuhara, J. Kang, C. Yu, H. Daga, K. Hotta, T. Yokoyama, H. Tanaka, M. Takeda, M. Hellmann, J. Sheng, F. Nathan, R. Yang, M. Nishio
  Abstract
  
  Loading...
- 28232
  
  +
  
  OA12 - A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC
  
  22:30 - 22:40 | Presenter: J Ji
  Abstract
  
  Loading...
28125

+
Best abstracts selected from submissions 7
- 16:20 - 17:00
- 11/09/2018
- Location: Jade Ballroom
- Type: Oral Session
- Track:
- 28228
  
  +
  
  OA13 - High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study
  
  22:20 - 22:30 | Presenter: X. Li, L. Zhang, D. Jiang, Y. Wang, A. Zang, C. Ding, M. Zhao, W. Su, Y. Zhang, D. Zhong, J. Wu, G. An, C. Zhang, X. Hu, G. Cheng, H. Wang, Z. Han, X. He, J. Liu, L. Liang, S. Zhang
  Abstract
  
  Loading...
- 28227
  
  +
  
  OA14 - Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
  
  22:30 - 22:40 | Presenter: Y. Cheng, J. Zhou, S. Lu, Y. Zhang, J. Zhao, H. Pan, Y. Chen, C. Chian, R. Bruns, A. Johne, J. Scheele, Y. Wu
  Abstract
  
  Loading...
28251

+
Parallel Session 1 - New strategy for neoadjuvant and adjuvant therapy
- 16:20 - 17:00
- 11/09/2018
- Location: Jade Ballroom
- Type: Oral Session
- Track:
- 28252
  
  +
  
  New perspectives on neoadjuvant and adjuvant chemotherapy
  
  04:00 - 04:25 | Presenter: P Bunn
  Abstract
  
  No abstract available for this presentation
- 28254
  
  +
  
  Discussion
  
  05:40 - 06:00 | Presenter: X Cai
  Abstract
  
  No abstract available for this presentation
- 28253
  
  +
  
  The translational research of neoadjuvant therapy
  
  20:25 - 20:50 | Presenter: W Zhong
  Abstract
  
  No abstract available for this presentation
28255

+
Parallel Session 2 - New strategy for local advanced NSCLC
- 16:20 - 17:00
- 11/09/2018
- Location: Crystall Ballroom 1
- Type: Oral Session
- Track:
- 28256
  
  +
  
  Optimal RT for local advanced NSCLC
  
  05:15 - 05:40 | Presenter: M Fan
  Abstract
  
  No abstract available for this presentation
- 28257
  
  +
  
  Discussions for a Next-Generation ROS1 Inhibitor Repotrectinib and Patient-reported Outcome(PRO)
  
  05:40 - 06:00 | Presenter: J Wang
  Abstract
  
  No abstract available for this presentation
28258

+
Parallel Session 3 - SCLC: developments and challenges
- 16:20 - 17:00
- 11/09/2018
- Location: Crystall Ballroom 3
- Type: Oral Session
- Track:
- 28259
  
  +
  
  Genomic study for SCLC: Is this a waste of time?
  
  04:25 - 04:50 | Presenter: D Carbone
  Abstract
  
  No abstract available for this presentation
- 28260
  
  +
  
  Role of surgical resection and chemotherapy for T1-2N0 SCLC
  
  05:15 - 05:40 | Presenter: Z Zhang
  Abstract
  
  No abstract available for this presentation
28247

+
Plenary Session - Immunotherapy for lung cancer
- 16:20 - 17:00
- 11/09/2018
- Location: Crystal Ballroom
- Type: Oral Session
- Track:
- 28248
  
  +
  
  Walking through the maze of first line immunotherapy for advanced NSCLC
  
  08:30 - 08:55 | Presenter: F Hirsch
  Abstract
  
  No abstract available for this presentation
- 28249
  
  +
  
  PDL1 expression versus TMB: Which should we use?
  
  09:20 - 09:45 | Presenter: G Lin
  Abstract
  
  No abstract available for this presentation
- 28250
  
  +
  
  Development of immunotherapy in China
  
  09:45 - 00:10 | Presenter: Q Zhou
  Abstract
  
  No abstract available for this presentation
28261

+
Parallel Session 1 - Oligomatastasis: what is optimal treatment?
- 16:20 - 17:00
- 11/10/2018
- Location: Crystall Ballroom 1
- Type: Oral Session
- Track:
- 28262
  
  +
  
  Oligomatastasis -Medical Oncologist perspective
  
  08:30 - 08:55 | Presenter: C Zhou
  Abstract
  
  No abstract available for this presentation
- 28263
  
  +
  
  Oligomatastasis Surgical Oncologist Perspective
  
  08:55 - 09:20 | Presenter: X Yang
  Abstract
  
  No abstract available for this presentation
- 28264
  
  +
  
  Oligomatastasis Radiation Oncologist Perspective
  
  09:20 - 09:45 | Presenter: C Xie
  Abstract
  
  No abstract available for this presentation
28265

+
Parallel Session 2 - Translational and clinical researches in China
- 16:20 - 17:00
- 11/10/2018
- Location: Crystall Ballroom 3
- Type: Oral Session
- Track:
- 28266
  
  +
  
  Translational researches for in late stage NSCLC
  
  09:20 - 09:45 | Presenter: B Gao
  Abstract
  
  No abstract available for this presentation
- 28267
  
  +
  
  Clinical Research in China
  
  09:45 - 00:10 | Presenter: Z Ma
  Abstract
  
  No abstract available for this presentation
28268

+
Parallel Session 3 - Diagnosis and treatment for small nodule in China
- 16:20 - 17:00
- 11/10/2018
- Location: Jade Ballroom
- Type: Oral Session
- Track:
- 28269
  
  +
  
  Early stage lung cancer: SBRT vs. surgery
  
  08:30 - 08:55 | Presenter: Z Zhu
  Abstract
  
  No abstract available for this presentation
- 28270
  
  +
  
  A genomic study: How to Improve limit of detection of lung cancer liquid biopsy
  
  09:20 - 09:45 | Presenter: X Wang
  Abstract
  
  No abstract available for this presentation
- 28271
  
  +
  
  How to deal with multiple pulmonary nodules
  
  09:45 - 00:10 | Presenter: W Li
  Abstract
  
  No abstract available for this presentation
28275

+
Special Symposia - Hotspots of Lung Cancer Translational Research
- 16:20 - 17:00
- 11/10/2018
- Location: Crystall Ballroom 3
- Type: Oral Session
- Track:
- 28276
  
  +
  
  Biomarkers for immunotherapy
  
  01:20 - 01:45 | Presenter: C Su
  Abstract
  
  No abstract available for this presentation

Session Information

ACLC 2018

IASLC Asia Conference on Lung Cancer 2018

Enter Virtual Meeting Access Code

+

Best abstracts selected from submissions 6

+

OA11 - First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (?10 mut/Mb): Results From CheckMate 227

+

OA12 - A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC

+

Best abstracts selected from submissions 7

+

OA13 - High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study

+

OA14 - Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

+

Parallel Session 1 - New strategy for neoadjuvant and adjuvant therapy

+

New perspectives on neoadjuvant and adjuvant chemotherapy

+

Discussion

+

The translational research of neoadjuvant therapy

+

Parallel Session 2 - New strategy for local advanced NSCLC

+

Optimal RT for local advanced NSCLC

+

Discussions for a Next-Generation ROS1 Inhibitor Repotrectinib and Patient-reported Outcome(PRO)

+

Parallel Session 3 - SCLC: developments and challenges

+

Genomic study for SCLC: Is this a waste of time?

+

Role of surgical resection and chemotherapy for T1-2N0 SCLC

+

Plenary Session - Immunotherapy for lung cancer

+

Walking through the maze of first line immunotherapy for advanced NSCLC

+

PDL1 expression versus TMB: Which should we use?

+

Development of immunotherapy in China

+

Parallel Session 1 - Oligomatastasis: what is optimal treatment?

+

Oligomatastasis -Medical Oncologist perspective

+

Oligomatastasis Surgical Oncologist Perspective

+

Oligomatastasis Radiation Oncologist Perspective

+

Parallel Session 2 - Translational and clinical researches in China

+

Translational researches for in late stage NSCLC

+

Clinical Research in China

+

Parallel Session 3 - Diagnosis and treatment for small nodule in China

+

Early stage lung cancer: SBRT vs. surgery

+

A genomic study: How to Improve limit of detection of lung cancer liquid biopsy

+

How to deal with multiple pulmonary nodules

+

Special Symposia - Hotspots of Lung Cancer Translational Research

+

Biomarkers for immunotherapy

Stay Connected